Jordan Park

Jordan Park

Healthcare & Biotech Analyst

Healthcare and biotech analyst focused on pharma pipelines, medtech adoption curves, and reimbursement dynamics. Former clinical research coordinator and later equity research analyst. Writes thesis-driven pieces that connect clinical catalysts, competitive landscapes, and valuation scenarios.

Articles 769

Jan 29, 2026 Finance

Tesla's Strategic Pivot to AI Sets Stage for Market Value Surge

Analyst Dan Ives Projects Tesla's Market Capitalization Could Hit $3 Trillion by Late 2026

Tesla, Inc. is advancing beyond its electric vehicle roots toward establishing itself as a frontrunner in artificial intelligence technology. Prominen...

Venezuela Revises Oil Sector Laws to Encourage Private Investment and Reform Industry Control
Jan 29, 2026 News & Politics

Venezuela Revises Oil Sector Laws to Encourage Private Investment and Reform Industry Control

Acting President Delcy Rodríguez enacts legislation as U.S. signals eased sanctions, setting stage for significant changes in Venezuela’s energy landscape

Venezuela's acting President Delcy Rodríguez has formalized a landmark oil industry reform law that transitions control from exclusive state dominanc...

Jan 29, 2026 Finance

Crypto Giants Invest Heavily in Super PAC Amid Regulatory Rift

Ripple and Coinbase pour millions into Fairshake yet diverge sharply on crypto regulation legislation

Ripple and Coinbase, two dominant players in the cryptocurrency sector, have collectively invested substantial funds into the super PAC Fairshake ahea...

New AI Regulations Set to Reshape the Industry Landscape in 2026
Jan 29, 2026 Business News

New AI Regulations Set to Reshape the Industry Landscape in 2026

California emerges as a pivotal regulatory hub, imposing stringent AI transparency and accountability standards

As of January 1, 2026, new legislation governing artificial intelligence (AI) technologies has come into force, signaling a shift in how both public a...

Kentucky Family Shelters Newborn Calf From Harsh Winter Cold
Jan 29, 2026 News & Politics

Kentucky Family Shelters Newborn Calf From Harsh Winter Cold

Amid Single-Digit Temperatures, Farm Family Rescues and Warms Newborn Calf, Demonstrating Adaptability During Extreme Weather

A Kentucky family witnessed a newborn calf born into severe cold weather conditions, prompting immediate rescue efforts to prevent further suffering. ...

Preparing for a Potential AI Stock Downturn in 2026: Strategies to Safeguard Your Portfolio
Jan 29, 2026 Business News

Preparing for a Potential AI Stock Downturn in 2026: Strategies to Safeguard Your Portfolio

Exploring defensive investment approaches amid concerns over a possible AI valuation correction

As enthusiasm around artificial intelligence (AI) stocks continues to surge, concerns about a potential bubble, especially in large-cap tech stocks li...

Jan 29, 2026 Finance

Thermo Fisher Scientific Outlines Earnings Impact of Clario Acquisition Amid 2025 Growth

Strong Q4 Performance Propels Optimistic 2026 Forecasts, Including EPS Boost from Pending Deal

Thermo Fisher Scientific reported better-than-expected earnings and revenue for Q4 2025, highlighting robust organic growth and operational excellence...

Global Powers Reaffirm Commitment to UN Amid US Board of Peace Proposal
Jan 29, 2026 News & Politics

Global Powers Reaffirm Commitment to UN Amid US Board of Peace Proposal

Trump’s expanded peace board concept faces resistance as international community backs traditional multilateral institutions

President Donald Trump's initiative to establish a Board of Peace intended to oversee the Gaza ceasefire and potentially mediate global conflicts has ...

Jan 29, 2026 Trade Ideas

Buy the Yield, Trade the Rebound: Pfizer at the Crossroads

High 6.6% yield, improving 2025 revenue cadence and cash flow — a yield-plus-recovery trade with clearly defined entry, stop and targets.

Pfizer is a cash-generative, high-yield large-cap pharma that looks cheap on headline multiples today. Recent quarterly results show revenue recovery ...

Trade Idea Long
Jan 29, 2026 Trade Ideas

Kyivstar Drives VEON Upside - A GARP Trade Around $54 ADS

Buy VEON ADS (VEON) on Kyivstar-led growth, Nasdaq visibility and pragmatic downside risk control

VEON (ADS) is a classic GARP (growth at a reasonable price) candidate right now: an ADS trading near $54.5 with clear, near-term operational upgrades ...

Trade Idea Long